Article metrics

Download PDFPDF

Original research
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

 

Online download statistics by month:

Online download statistics by month: February 2020 to August 2020

AbstractFullPdf
Feb 2020312312161
Mar 202023023076
Apr 2020148148101
May 2020555564
Jun 2020565630
Jul 2020707021
Aug 2020454530
Total916916483